Autologous bone marrow-derived mesenchymal stem cells for treatment of heart muscle damage
This study aims to determine the safety and feasibility of direct intra-myocardial injection of autologous bone marrow mesenchymal stem cells (BM-MSCs) in adult subjects undergoing coronary artery bypass graft (CABG) or transmyocardial revascularization (TMR).
Read More
Product Information for
Autologous bone marrow-derived mesenchymal stem cells for treatment of heart muscle damage